Background
Delirium is an acute state of confusion with fluctuating symptoms of disturbed attention and cognition commonly precipitated by stress, such as surgery, in frail patients [
1]. Besides unpleasant while ongoing, a delirium carries the risk of increased mortality and long-term sequela of cognitive functions [
2]. Although much is unknown, the delirium pathogenesis is thought to involve disturbed neurotransmission and/or induced inflammation with microglial activation [
3]. The neuroinflammatory hypothesis suggest that delirium symptoms arise as central immunity is activated by initial peripheral inflammation that convey to the brain [
4,
5].
While delirium increases the risk of dementia, dementia is also a delirium risk factor [
6‐
8]. The most common cause of dementia is Alzheimer’s disease (AD), a neurodegenerative disorder with pathological hallmarks amyloid plaques and neurofibrillary tangles [
9]. Already at a preclinical stage with evident neuropathology is AD found to increase the risk of delirium [
10,
11]. Neuroinflammation with microglial activation and astrogliosis also plays a role in AD [
12]. Thus, delirium and dementia etiology are intertwined with shared pathogenic mechanisms such as microglial activation and other facets of neuroinflammation [
13].
Microglia, the resident immune cells of the brain, express the innate immune receptor triggering receptor expressed on myeloid cells 2 (TREM2) [
14]. Variants of
TREM2 are known as dementia risk factors [
15‐
17] linking
TREM2 to age-related neurodegeneration. The transmembrane TREM2 receptor undergoes ectodomain shedding releasing soluble TREM2 (sTREM2) [
18] (Fig.
1a). In the cerebrospinal fluid (CSF) of AD patients, sTREM2 is reported increased [
19,
20]. An even higher level is observed at the prodromal mild cognitive impairment (MCI) stage of AD [
21]. Moreover, the level of CSF sTREM2 correlates positively with the core CSF biomarkers amyloid beta 1–42 (Aβ42), total-tau (t-tau), and phosphorylated-tau (p-tau) in asymptomatic patients, which further suggests an early involvement of reactive microgliosis [
22,
23].
In the present study, we analyzed the CSF sTREM2 level in patients with or without pre-existing dementia. The patients all suffered a hip fracture with subsequent hospital admission and surgery that for some led to delirium, and we evaluated CSF sTREM2 as a putative biomarker of delirium. Given the abovementioned biomarker correlations in AD, we also examined the relation between CSF sTREM2 and AD core biomarkers, CSF Aβ42, t-tau, and p-tau. For the potential influence of a peripheral trauma, we investigated how the CSF sTREM2 level related to time after hip fracture. We also included a patient group with delirium associated with a medical condition to evaluate potential similarities and dissimilarities to hip fracture-triggered delirium.
Methods
Hip fracture cohort
The hip fracture patients, which were recruited from the Oslo Orthogeriatric trial (OOT), were admitted to the Oslo University Hospital Ullevål (OUS, Ullevål) between September 2009 and January 2012 [
24,
25]. Delirium was assessed using the Confusion Assessment Method (CAM) [
26] by the study physician or a study nurse. Delirium was assessed daily preoperatively and until the fifth postoperative day or in case of delirium until discharge. Pre-fracture dementia status was decided by consensus and based on the International Classification of Diseases − 10 (ICD-10) criteria for dementia by an expert panel as previously described [
25].
The hip fracture patients (
n = 120) were grouped both according to delirium and dementia status into either of the following groups (see Fig.
1a and Table
1)
1.
No delirium during the hospital stay (no delirium) (
n = 54)
a.
No delirium, and without pre-fracture dementia (n = 44)
b.
No delirium, but pre-fracture dementia (n = 10)
2.
Delirium during the hospital stay (delirium) (
n = 65)
a.
Delirium, but without pre-fracture dementia (n = 15)
b.
Delirium with pre-fracture to dementia (n = 50)
Delirium patients included prevalent delirium (those that developed delirium preoperatively; n = 41) and incident delirium (postoperative delirium in those free from delirium before surgery; n = 21). The sub-classification of delirium onset was applied for delirium onset analyses.
Medical delirium cohort
The medical delirium cohort was recruited from a prospective study at the same hospital in which 244 patients who underwent lumbar puncture (LP) due to suspicion of acute central nervous system (CNS) infection were included. Patients were included between January 2014 and December 2015. The patients included in the current study (n = 26) were those in which a CNS infection was ruled out and delirium triggered by another medical condition was considered the most likely explanation for the acute cognitive symptoms. Pneumonia and urinary tract infection were the most frequent diagnoses in this group. All patients had encephalopathy at the time of the LP. Delirium was assessed either by the study physician with CAM, or by clinical evaluation of treating physician in the medical ward. Dementia status was set from the hospital records. These delirium patients formed a separate group labeled “medical delirium” afflicted by delirium with another precipitating factor than the hip fracture patients.
CSF sampling, handling, and storage
In the hip fracture cohort, CSF was collected in connection with the orthopedic surgery at the onset of spinal anesthesia before administrating the anesthetic agents. CSF of patients with medical delirium was obtained during the diagnostic lumbar puncture (LP) at a median of 1 day after CNS symptoms developed. CSF was collected in polypropylene tubes and centrifuged as soon as possible, and supernatant aliquots were stored in polypropylene tubes at − 80 °C [
27].
Table 1
Characteristics of the hip fracture and medical delirium patients
PATIENTS
WITHOUT
DEMENTIA
|
N
|
59
|
44
|
15
|
7
|
8
|
17
|
Age (years) | 84 (10) | 84 (16) | 85 (7) | 86 (11) | 85 (7) | 66 (16) |
Gender |
Male | 17 | 11 | 6 | 3 | 3 | 10 |
Female | 42 | 33 | 9 | 4 | 5 | 7 |
Time to surgery (h)* | 23 (17) | 23 (17) | 27 (15) | 22 (19) | 30 (14) | – |
CSF sTREM2 ng/ml | 7.8 (5.7) | 7.4 (5) | 11.1(11) | 11.6 (5) | 7.8 (15) | 5.6 (8) |
CSF biomarkers |
N
|
57
|
44
|
13
|
5
|
8
| |
CSF Aβ42 (pg/ml) | 446 (367) | 479 (414) | 283 (224) | 283 (232) | 295 (253) | – |
CSF t-tau (pg/ml) | 369 (276) | 356 (198) | 564 (638) | 564 (369) | 587 (795) | – |
CSF p-tau (pg/ml) | 57(35) | 54 (33) | 78 (68) | 78 (19) | 88 (89) | – |
CSF Aβ42 cut-off (< 530 pg/ml) |
Below | 37 | 26 | 11 | 4 | 7 | – |
Above | 20 | 18 | 2 | 1 | 1 | – |
CSF p-tau cut-off (≥ 60 pg/ml) | | | | | |
Above | 26 | 17 | 9 | 4 | 5 | – |
Below | 31 | 27 | 4 | 1 | 3 | – |
CSF t-tau cut-off (> 350 pg/ml) | | | | | |
Above | 32 | 23 | 9 | 5 | 4 | – |
Below | 25 | 21 | 4 | – | 4 | – |
PATIENTS
WITH
DEMENTIA
|
N
|
61
|
10
|
50
|
13
|
33
|
9
|
Age (years) | 86 (9) | 86.5 (17) | 85(9) | 87 (8) | 85 (8) | 71(23) |
Gender |
Male | 16 | 1 | 15 | 5 | 8 | 6 |
Female | 45 | 9 | 35 | 8 | 25 | 3 |
Time to surgery (h)* | 26 (28) | 27 (16) | 26(31) | 18(19) | 38 (24) | – |
CSF sTREM2 ng/ml | 7.0 (7.8) | 9.2 (16) | 7.3 (7) | 6.1 (10) | 8.5 (8) | 6.9(6.7) |
CSF biomarkers, N |
60
|
9
|
50
|
13
|
33
| |
CSF Aβ42 (pg/ml) | 265 (166) | 317 (290) | 258 (172) | 268 (219) | 269 (174) | – |
CSF t-tau (pg/ml) | 408 (379) | 441 (503) | 408 (366) | 385 (293) | 407 (329) | – |
CSF p-tau (pg/ml | 55 (41) | 58 (57) | 55 (35) | 55 (47) | 55 (31) | – |
CSF Aβ42 cut-off (< 530 pg/ml) |
Below | 55 | 7 | 47 | 11 | 1 | – |
Above | 5 | 2 | 3 | 2 | 32 | – |
CSF p-tau cut-off (≥ 60 pg/ml) | | | | | |
Above | 24 | 4 | 20 | 5 | 13 | – |
Below | 36 | 5 | 30 | 8 | 20 | – |
CSF t-tau cut-off (> 350 pg/ml) | | | | | |
Above | 38 | 5 | 33 | 8 | 22 | – |
Below | 22 | 4 | 17 | 5 | 11 | – |
CSF sTREM2 measurements
CSF sTREM2 was assayed by a sensitive TREM2 enzyme-linked immunosorbent assay (ELISA) as previously described [
22]. Briefly, plates were incubated with an anti-humanTREM2 polyclonal capture antibody overnight at 4 °C (AF1828, R&D Systems, Minneapolis, MN, USA) and TREM2 detected by a mouse anti-human TREM2 monoclonal HRP-conjugated antibody (1 h incubation at room temperature (RT);SEK11084, Sino Biologics, Beijing, China). Samples were assayed in duplicates (2 h incubation at RT) with known cohort (hip fracture or medical), but with the clinical identity unknown to the operator. Samples with extreme values were assayed again, including the same and an increased sample dilution to verify measurements in the repeated assay. Two internal standard (CSF) samples were included in each assay to assess interday variability and used to adjust the medical delirium cohort which was assayed separately from the hip fracture cohort, with a final CV < 10% across assays.
CSF Aβ, t-tau, and p-tau measurements
CSF levels of t-tau, p-tau, and Aβ42 were quantified with commercially available ELISAs; Innotest® hTau Ag, Innotest® phoshoTau (181P), and Innotest® β-amyloid 1–42 as previously described [
28‐
30] (Fujirebio Europe, Gent, Belgium). CSF Aβ peptide levels were determined with CSF Aβ
1–38 (Aβ38), Aβ
1–40 (Aβ40), and Aβ
1–42 (Aβ42) MSD Triplex assay (Meso Scale Discovery, Rockwilly, MA, USA). All these analyses were performed at the Clinical Neurochemistry Laboratory at Sahlgrenska University Hopsital, Mölndal, Sweden. CSF cut-off for pathological level was < 530 pg/ml (Aβ42+/−), ≥ 60 pg/ml (p-tau+/−), and > 350 pg/ml (t-tau +/−) [
31].
Statistical analyses
Analyses were performed by parametric or non-parametric statistics as appropriate depending on the data distribution. Data distribution was assessed by histogram, probability-probability (P-P), and quantile-quantile (Q-Q) plots. As CSF sTREM2 raw data were skewed, continuous data are reported by median (interquartile range (IQR)) and group differences analyzed by Mann-Whitney or Kruskal-Wallis test. p values of group comparisons were obtained by Mann-Whitney test, unless otherwise reported. The correlation analyses are reported by Spearman’s rho correlation coefficient (rs).
Multiple linear regression was used for analyses with multiple predictor variables. For stepwise multiple linear regression, predictors were included based on significance in univariate analyses and biological grounds, including predictors with highest assumed degree of explained variability first. The data transformation by the natural logarithm (ln) (ln(CSF sTREM2 ng/ml) approximated a normal distribution and was therefore applied for analyses requiring parametric tests (linear regressions). Standardized residuals in linear regressions met the criteria of normal distribution. In regression analyses with delirium, no delirium was coded as 0 and delirium as 1. In linear regressions with delirium onset; no delirium was coded as 0, incident delirium as 1, and prevalent delirium as 2.
All hypotheses were two-sided and the reported p values are therefore two-tailed. The significance level was set at p < 0.05. Statistical analyses were performed by the Statistical Package for Social Sciences (SPSS, versions 24 and 25; IBM, Armonk, NY, USA). Graphical illustrations were created with GraphPad Prism (version 7.04 Graph Pad Software, La Jolla, CA, USA).
Discussion
This is the first study to report on CSF sTREM2 level in delirium. Moreover, the study differs from previous investigations by analyzing CSF sTREM2 as a biomarker in a dementia population of an advanced age. Although we did not see an overall effect of delirium, analyzing patients with and without pre-existing dementia separately revealed a clear differential effect on CSF sTREM2 and interrelations to other biomarkers in these two populations. Delirium increased CSF sTREM2 only in patients without pre-existing dementia. TREM2 is a highly microglial-specific receptor, and ectodomain shedding of TREM2 releases sTREM2 that then presumably drains to CSF [
18]. The level of sTREM2 in the brain reflects amyloid-induced microglial activation in transgenic mice with aging as judged by PET imaging [
39]. Patient studies also suggest that microglial-derived CSF sTREM2 increases with a general glial-mediated immune response, e.g., a positive relation with the astroglial CSF-marker YKL-40 [
19]. We therefore argue that increased sTREM2 in delirium without pre-existing dementia is due to central microglial activation. We speculate that CSF sTREM2 increases only in delirium patients without dementia because the pathogenic process is less complex and the inflammatory process will more clearly stand out in this patient group.
Increased CSF sTREM2 with delirium triggered by hip fracture was most prominent in incident delirium, i.e., in CSF sampled before the delirium syndrome was evident in non-demented patients. Medical delirium patients all suffered encephalopathy at the time of CSF sampling. Interestingly, patients with medically induced delirium displayed lower CSF sTREM2 relative to patients with hip fracture-triggered delirium. This effect was close to significant when compared to incident delirium patients alone. Thus, stratification of delirium-afflicted patients suggests that CSF sTREM2 increases transiently prior to delirium onset, but then declines. An early but transient glial response in delirium is supported by increased levels of other CSF biomarkers of immune responses in incident delirium, such as neopterin [
40] and astroglia-derived S-100β [
41]. Thus, CSF sTREM2 is a promising biomarker of microglial activation that is presumably more usable to detect transient responses, which is consistent with TREM2 having a rapid cell surface turnover (< 1 h) [
42]. Longitudinal studies and continuous CSF sampling of delirium patients could confirm or refute this hypothesis, although it might be ethical challenging to conduct such a study with fragile patients.
In contrast, delirium did not alter the CSF sTREM2 level in patients with pre-existing dementia nor did dementia by itself affect CSF sTREM2. CSF sTREM2 is reported increased in younger and CSF biomarker-selected AD patients (mean ≈ 65–70 years) (e.g., [
19,
20]). We speculate that superimposed dementia with Aβ deposits and tau inclusions continuously stimulating microglial activation diminish the effect of delirium on microglial response and sTREM2 release. Such proteinaceous neuropathology might also lead to an increased protein turnover preventing a raised interstitial sTREM2 level in demented patients. Importantly, as compared to many other CSF-dementia studies, the patients examined by us were markedly older (median ≈ 85 years) and not biomarker-selected and their dementia pathogenesis was likely more heterogeneous [
43,
44]. Thus, comorbidities and advanced age could have diluted the direct link from AD neuropathology to enhanced sTREM2 release and CSF sTREM2.
The initial hip fracture trauma presumably activated peripheral immune responses in the patients. The neuroinflammatory hypothesis of delirium suggests that brain dysfunctions and clinical presentation are secondary to peripheral immune activation [
4]. Dementia patients displaying increased CSF sTREM2 with waiting time for acute hip fracture surgery is consistent with this theory. That this only was evident among dementia patients also support the concept of primed more easily activated microglia in neurodegenerative disease compared to a healthy brain [
45,
46].
Exploring relations between CSF biomarkers may provide better pathogenic understanding by hinting to simultaneously ongoing processes in the brain. CSF Aβ and t-tau/p-tau markers related positively to CSF sTREM2 only in dementia patients with delirium, possibly suggesting somewhat distinct biological processes of delirium with or without pre-existing dementia. CSF sTREM2 related positively to CSF Aβ42 in the demented patients, essentially all of which were below the CSF Aβ42 cut-off level. Clinical data suggest that Aβ42 is sequestered by senile plaques, long before symptom onset leading to a pronounced drop in CSF Aβ42. This low CSF Aβ42 level is then stable in the individual patient [
47,
48]. Thus, a positive relation between CSF Aβ42 and CSF sTREM2 in demented patients does presumably not relate to the extent of amyloid deposition. Instead, it is more likely to reflect shared protein synthesis and metabolism of Aβ precursor protein (AβPP) and TREM2, an idea which is consistent with our findings of positive relations also to the shorter and far less plaque-sequestered C-terminal truncated peptides Aβ38 and Aβ40 [
49]. AβPP and TREM2 share common features of ectodomain shedding by ADAMs α-secretase and subsequent γ-secretase cleavage [
18,
50‐
52], and although they are released by different cell types, one can speculate whether both play a role to similar physiological functions that involve neuronal-glial communication.
An expanding literature links Aβ production to neuronal and synaptic activity and biological rhythms, e.g., sleep-wakefulness [
53,
54]. We speculate that delirium in dementia patients triggers neuronal network activation with concomitant enhanced release of Aβ peptides, t-tau/p-tau, and sTREM2; all reflected by a transiently increased CSF level. Interestingly, a recent study demonstrated with isotope labeling kinetics that increased CSF-tau in early AD reflects neuronal tau-synthesis and positively correlates with amyloid-PET, but not tau-PET [
55]. Thus, CSF- t-tau/p-tau levels might also reflect neuronal activity associated with amyloid, and not simply axonal damage and tauopathy as previously thought. There are reports of neuronal network disturbances in Alzheimer’s disease as well as delirium [
56,
57]. Thus, our observations of positive CSF-biomarker associations only in demented patients might be due to the susceptibility of frail brains to neuronal network dysfunctions.
CSF sTREM2 and tau markers interrelated in several studies of AD cohorts, yet in different subpopulations [
19,
20,
58]. CSF sTREM2 clearly increased in a cohort of suspected non-amyloid pathology (SNAP) patients having cognitive dysfunctions and only positive CSF-tau biomarkers indicating that elevated CSF sTREM2 can occur independent of amyloid pathology [
58]. Indeed, inclusion of p-tau in linear regression analyses showed that p-tau was the best sole predictor. Including CSF Aβ42 as a second predictor better explained CSF sTREM2 variability in the dementia group, while incorporating variables age and delirium did not. Thus, in dementia patients, the existing neuropathology seemed to exceed any delirium effects again suggesting pathogenic differences of delirium with and without pre-existing dementia.
With aging, dementia does not well relate to Aβ pathology and tauopathy, presumably because of increased importance of cerebrovascular comorbidity [
59]. The high median age and limited age distribution of the study cohort likely explain why CSF sTREM2 did not relate to age. There might also be a ceiling effect of CSF sTREM2 with aging, which would be worth further studying. CSF sTREM2 increases with aging in several studies that involved younger patient populations [
20‐
22]. Indeed, there was a tendency of a positive correlation with aging among patients with medical delirium that included younger individuals.
Acknowledgements
Foremost, we would like to thank all patients included in the study. We would like to thank the staff at the Department of Orthopedic Surgery, Department of Anesthesiology, Department of Internal Medicine, and Department of Neurology, and from the Department of Infectious Diseases, we would like to thank the principal investigator of the CNS infection study Dr. Vidar Ormaasen and prof Dag Kvale who were responsible for the biobank at Oslo University Hospital. Kjetil Røysland at the Oslo Centre for Biostatistics and Epidemiology (OCBE) at UiO and Oslo University hospital (OUS) is greatly acknowledged for providing statistical advice. HZ is a Wallenberg Academy Fellow. KB holds the Torsten Söderberg Professorship in Medicine.